SCHEMBL22808207

SCHEMBL22808207

CC(C)(C)OC(=O)N1c2ccccc2Oc2cc(NC(=O)OCc3ccccc3)ccc21

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 6/20 0.57
P2RX1 P51575 1/20 0.57
P2RX3 P56373 1/20 0.57
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
TSHR P16473 1/20 0.53
RAB9A P51151 1/20 0.53
ATM Q13315 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MGLL Q99685 3/20 0.45
RORC P51449 3/20 0.42
ROCK2 O75116 2/20 0.42
POLB P06746 1/20 0.41
ENPP2 Q13822 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22808205 0.85 P2RX4 (0.52) P2RX4P2RX1P2RX3MAPTSMN1; SMN2
SCHEMBL22808203 0.84 TP53 (0.61) P2RX4P2RX1P2RX3NPC1ALDH1A1
SCHEMBL26119913 0.75 P2RX4 (0.52) P2RX4P2RX1P2RX3MAPTSMN1; SMN2
SCHEMBL9177839 0.75 NPC1 (0.53) NPC1ALDH1A1TP53MAPTTSHR
SCHEMBL7043026 0.74 POLB (0.62) NPC1ALDH1A1TP53MAPTTSHR
SCHEMBL25840355 0.74 P2RX4 (0.79) P2RX4P2RX1P2RX3NPC1MAPT
SCHEMBL29395154 0.74 P2RX4 (1.00) P2RX4P2RX1P2RX3NPC1ALDH1A1
SCHEMBL26478548 0.74 P2RX4 (1.00) P2RX4P2RX1P2RX3NPC1ALDH1A1
SCHEMBL31722365 0.74 P2RX4 (1.00) P2RX4P2RX1P2RX3NPC1ALDH1A1
SCHEMBL6510132 0.74 NPY2R (0.52) NPC1ALDH1A1TP53MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870646-B2 Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis UNIVERSITY OF ST. THOMAS (US) 2020-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870646-B2 Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis OXA1L, IMMT, TBCD P2RX4 4491/4885P2RX1 4264/4885P2RX3 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.